Avalyn Pharma Inc. officer Howard Lazarus filed a Form 144 notice on November 17, 2026, disclosing a proposed sale of 53,200 shares of common stock acquired through stock option exercises, with an aggregate market value of $1,583,232.00.

Key Highlights

  • Filer and role: Howard Lazarus, identified as an Officer of Avalyn Pharma Inc.
  • Shares proposed for sale: 53,200 shares of common stock, with an aggregate market value of $1,583,232.00.
  • Source of shares: Shares were acquired through the exercise of stock options from the issuer on November 17, 2026, with cash payment on the same date.
  • Shares outstanding: 44,521,494 shares of common stock outstanding, according to the filing.
  • Approximate date of sale: November 17, 2026, through broker Morgan Stanley Smith Barney LLC Executive Financial Services.
  • Rule 10b5-1 plan: The filing indicates a plan adoption date of July 30, 2026.
  • Prior sales in past 3 months: The filing reports nothing to report under securities sold during the past 3 months.

Avalyn Pharma Officer Proposes Stock Option-Linked Share Sale Under Rule 144

According to the Form 144 notice filed with the U.S. Securities and Exchange Commission, Howard Lazarus, an officer of Avalyn Pharma Inc. (NASDAQ:AVLN), disclosed a proposed sale of 53,200 shares of the company's common stock. The filing lists an aggregate market value of $1,583,232.00 for the shares to be sold. The broker named in the filing is Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004.

The filing states that the shares were acquired on November 17, 2026, through the exercise of stock options granted by the issuer, with payment made in cash on the same date. A remark in the filing notes that "the securities to be sold were and will be received upon the exercise of stock options over the next three months" and that "the dates of acquisition and payment were and will be the dates of exercise/sale." The filing also indicates that Lazarus is relying on a Rule 10b5-1 trading plan adopted on July 30, 2026.

The Form 144 covers only a proposed sale notice and does not confirm that any transaction has been completed. The filing reports no sales of Avalyn Pharma securities by Lazarus during the three months preceding this notice. As of the filing, Avalyn Pharma disclosed 44,521,494 shares of common stock outstanding. Avalyn Pharma Inc. is listed on NASDAQ, with its principal address at 105 W First Street, Boston, Massachusetts 02127, according to the filing.

What Was Disclosed

Howard Lazarus, an officer at Avalyn Pharma Inc., filed a Form 144 on November 17, 2026, proposing to sell 53,200 common shares valued at $1,583,232.00, acquired via stock option exercise, under a Rule 10b5-1 plan adopted July 30, 2026.